Objectives To study the relationship between gastrin expression and proliferating cell nuclear antigen (PCNA),argyrophilia nucleolar organizer regions(AgNORs) in colorectal cancer (CC) tissue. Methods Gastrin and PCNA expression in 48 cases of CC tissue and cancer adjacent mucosa was detected by immunohistochemistry techniques. AgNORs was determined with argyrophilia stain. Results The positive rate of gastrin in CC tissue was 39 58%, that of well differentiated adenocarcinoma was higher than the poorly differentiated and mucinous adenocarcinoma( P

Objective To study the relationship between gastrin and c-myc, c-fos expression in colorectal cancerous tissue and the mechanism of gastrin effect on colorectal cancer.Methods The gastrin and c-myc, c-fos expression in 48 cases of colorectal cancerous tissue and cancer-adjacent mucosa were detected with immunohistochemistry techniques. Results　The positive rate of gastrin in colorectal cancerous tissue was 39.58%. The rate of the well differentiated adenocarcinoma was higher than that of the poorly differentiated and mucinous adenocarcinoma(P＜0.05). The positive rates of c-myc and c-fos in colorectal cancerous tissue were higher than those in cancer-adjacent and normal mucosa. The positive rate of c-myc and c-fos in the group with gastrin positive expression were 78.94% and 73.68%, higher than those in the group with negative gastrin expression(37.93% and 31.04%). Conclusion Some of colorectal cancer cells formed and secreted gastrin through autocrine. The increase of c-myc, c-fos etc oncogene expression probably stimulate the cancer cells proliferation.

Objective To study the expression and significance of proliferating cell nuclear antigen (PCNA) and argyrophilia nucleolar organizer regions (AgNORs) in colorectal carcinoma (CRC) and carcinoma adjacent mucosa (CAM).Methods The expression of PCNA in 48 cases of colorectal carcinoma tissue, CAM and 10 cases of normal mucosa was detected by immunohistochemistry techniques. AgNORs was determined with argyrophilia stain. Results The PCNA labeling index (PCNA LI) and AgNORs count in CRC were higher than that in CAM and normal mucosa( P

Objective To observe the effect of caffeic acid phenethyl ester (CAPE) on proliferation, cell cycle and apoptosis of human colorectal cancer cell line SW480.MethodsSW480 cells were treated with CAPE .The proliferative status of cells was measured by methabenzthiazuron (MTT) assay. Cell cycle was analyzed by flow cytometry (FCM) . Apoptosis was detected by FCM. The apoptosis cells were detected by TUNEL staining.ResultsCAPE inhibited growth of SW480 cells in a dose-dependent and time-dependent manner. Cell G_0/G_1 phase rate increased, S phase rate decreased and cell apoptosis rate increased after exposed to CAPE in a dose dependent manner (2.5, 5.0 and 10mg/L). Apoptosis cells increased after the treatment of CAPE.ConclusionsCAPE inhibits the proliferation and induces apoptosis in human colon cancer cell line SW480.The effect mechanism is related to arrest the cell cycle G_1 and induce cell apoptosis.

Objective To investigate the relationship between ? catenin expression and colorectal adenoma with canceration. Methods The expression levels of ? catenin in 25 cases of normal colorectal mucosa (NCM), 42 cases of colorectal adenoma (CA), and 19 cases of colorectal adenoma with canceration (CAC) were detected by immunohistochemistry. Results ? catenin expression was detected on the cell membrane in normal colorectal mucosa. Reduced membrane expression, cytoplasmic and nuclear expression were detected in the colorectal adenoma and adenoma with canceration. The cytoplasmic and nuclear expression rate of ? catenin was 89.5% in colorectal adenoma with canceration, significantly higher than that in colorectal adenoma(42 9%, P

0.05) Conclusion Subtotal colectomy and intraoperative colonic irrigation are effective methods for management of obstructing carcinoma in the left colon To select an effective technique depends on the analysis of the practical situations and evaluation of the idiographic complexions.

OBJECTIVE:To investigate the role of clinical pharmacists on drug therapy for acute exacerbations of chronic ob-structive pulmonary disease(AECOPD)patients with benign prostatic hyperplasia(BPH). METHODS:Clinical pharmacists partici-pated in drug therapy for a AECOPD patient with BPH. According to clinical guideline and relevant literatures,based on the history of disease,the characteristics of bronchodilators and the symptoms of acute urinary retention,it was suggested to stop taking Ip-ratropium bromide solution for inhalation but receive Finasteride capsules 5 mg,po,qd,to reduce prostate volume and improve ob-struction+Terazosin hydrochloride tablets 2 mg,po,qd,to relax urethral smooth muscle;the occurrence of ADR was monitored closely. Salmeterol xinafoate and fluticasone propionate powder for inhalation was suggested and medication guidance for patients af-ter discharge was given by clinical pharmacists. RESULTS:Physicians adopted some suggestions of clinical pharmacists. The pa-tient was stable and had no dysuria. The patient was allowed to leave the hospital with drugs. CONCLUSIONS:Rational use of bronchodilators is directly related to the remission of clinical symptoms and prognosis in AECOPD patients. In view of patient's dis-ease history,drug characteristics and clinical symptoms,clinical pharmacists point to possible risks of anticholinergics use,and as-sist physicians to formulate and adjust therapy plan so as to guarantee the safety and effectiveness of drug use.

The poly(ADP-ribose) polymerases (PARPs) is an important group of enzymes in DNA repair pathways, especially the base excision repair (BER) for DNA single-strand breaks (SSBs) repair. Inhibition of PARP in DNA repair-defective tumors (like those with BRAC1/2 mutations) can lead to cell death and genomic instability, what is so called "synthetic lethality". Currently, PARP inhibitors combined with cytotoxic chemotherapeutic agents in the treatment of BRCA-1/2 deficient cancers are in the clinical development. In this review, we will be focused on the development of combination application of PARP inhibitors with other anticancer agents in clinical trials.

Objective To investigate the effect of IVIG on pre-existing anti-HLA-A2 Ab levels and graft skin survival.Methods C57BL/6 wild type mice were sensitized to HLA-A2 by intraperitoneal injec-tion (IP) of HLA-A2 TgN mouse spleen cells (C57BL/6-TgN [HLA-2.1]1Enge SC) expressing human HLA-A2 at day 0, week 3 and 4.Sensitized mice were respectively treated with human IVIG , albumin, gly-cine, or PBS for 5 days during week 7.Skin transplantation from TgN mice to C57BL/6 wild type mice was performed at week 10 .Efficacy of IVIG DES was assessed by measuring anti-HLA Ab levels by ELISA pre-/post-Rx and graft skin survival was monitored daily post-Tx.Results Changes of HLA-A2-IgG levels:IgG HLA-A2 class I Ab levels in all groups predictably increased from baseline following spleen cell IP and peaked at week 4 ( P <0.01 ) , indicating sensitization .IVIG-treated mice showed significantly lower IgG Ab levels vs.albumin, glycine and PBS-treated at week 9 post-desensitization ( P <0.01).IgG quickly increased to extremely high levels in all groups following skin transplantation ( P <0.01 ) .Graft skin sur-vival between Rx-groups were similar with all rejecting at about 7 days post-transplantation ( P >0.05 ) . Conclusion However, IVIG alone does not inhibit anti-HLA class I Ab production after skin transplanta-tion or prolong SG survival , indicating combination of IVIG with other immunosuppressant or more optimal protocol for desensitization might show more efficacy and should be under explored .